Who We Are
Delivering on our promise for patients
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
We are led by an experienced international management team. Our proprietary product pipeline and next-generation antibody technologies are the result of our strong company culture and a deep passion for innovation. We are inspired by nature and the power of the immune system to transform cancer treatment.
Office Locations
We are a leading international biotech with a global footprint
Built on a foundation of science, innovation and drug discovery and development, we have offices and research centers where we collaborate to transform the way cancer is treated.
We employ more than 1000 people globally, including at our headquarters in Denmark and core facilities in the Netherlands and the United States. In addition, we have a regional office in Japan.
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Phone +45 7020 2728
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab B.V.
Visiting Address
Uppsalalaan 15
3584 CT Utrecht
The Netherlands
Postal Address
P.O. Box 85199
3508 AD Utrecht
The Netherlands
Phone +31 30 2 123 123
CVR Utrecht 30169902
VAT no. NL8095.75.000.B.01
Genmab U.S., Inc.
777 Scudders Mill Road
Plainsboro, NJ 08536
USA
Phone +1 609 430 2481
Genmab K.K.
Midtown Tower
9-7-1 Akasaka, Minato-ku
Tokyo 107-6235
Japan
Chamber of Commerce no.: 0104-01-14036
Contact us
Have a general inquiry?
Contact us for medical information and queries about a specific compound or program or how to participate in a clinical trial.
Rest assured, we will handle your personal data in accordance with our Privacy Policy.
Join our mission
Be a part of our team and help transform the future of cancer treatment
Putting our expertise to work
See how we put our in-depth knowledge of antibody biology into action
News, events and more
Get the latest stock information and news about Genmab